LX6171 Low Dose

Phase 2Small molecule

LLexicon Pharmaceuticals

LX6171 Low Dose is one of 18 small molecule programs targeting Memory Impairment. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Memory ImpairmentActive, not recruiting

Memory ImpairmentPhase 2

Active, not recruiting

Competition

Competitive Landscape

21 competitors in Memory Impairment

#DrugCompanyPhaseTrials

Vyvanse

Takeda

Approved

1 2

Celexa

AbbVie

Approved

1 3

Aricept

Eisai

Approved

1 4

Nicorette

Sensipar

Effexor

WWyeth-Lederle Vaccines

Approved

1 7

Dilantin

VViatris Specialty LLC

Approved

1 8

Lamictal

GGlaxo Dba Glaxosmithkline

Approved

1 9

Proair HFA

GGlaxo Dba Glaxosmithkline

Minocin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Memory Impairment1 trial

Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment

Completed·LLexicon Pharmaceuticals·Phase 2·NCT00691808·103 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LX6171 Low Dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LX6171 Low Dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LX6171 Low Dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Lexicon Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: LLexicon Pharmaceuticals

LX6171 Low Dose

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Memory Impairment1 trial

References

Drug Info

Quick Facts

Related News